日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma

巨胞饮作用和血管生成决定肺鳞状细胞癌对 mTOR 抑制剂的反应

Brady, Morgan R; Matulionis, Nedas; Christofk, Heather R; Garon, Edward B; Lisberg, Aaron; Shackelford, David B; Momcilovic, Milica

Adequacy of Immune Checkpoint Inhibitor-Associated Thyroid Function Monitoring After Therapy

免疫检查点抑制剂治疗后甲状腺功能监测的充分性

Velez, Maria A; Kang, Elliot S; Thompson, Chester A; Lind-Lebuffe, Jackson; Shen, Collin; Park, Seung Jun; Han, Andy; Gower, Arjan; Li, Daniel; Rochigneux, Philippe; Grogan, Tristan R; Elashoff, David A; Garon, Edward B; Lisberg, Aaron

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

达托泊单抗德鲁替康对比多西他赛治疗既往接受过治疗的晚期或转移性非小细胞肺癌:随机、开放标签的 III 期 TROPION-Lung01 研究

Ahn, Myung-Ju; Tanaka, Kentaro; Paz-Ares, Luis; Cornelissen, Robin; Girard, Nicolas; Pons-Tostivint, Elvire; Vicente Baz, David; Sugawara, Shunichi; Cobo, Manuel; Pérol, Maurice; Mascaux, Céline; Poddubskaya, Elena; Kitazono, Satoru; Hayashi, Hidetoshi; Hong, Min Hee; Felip, Enriqueta; Hall, Richard; Juan-Vidal, Oscar; Brungs, Daniel; Lu, Shun; Garassino, Marina; Chargualaf, Michael; Zhang, Yong; Howarth, Paul; Uema, Deise; Lisberg, Aaron; Sands, Jacob

Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study

达托泊单抗德鲁西替康治疗具有可靶向基因组改变的晚期或转移性非小细胞肺癌:来自 II 期 TROPION-Lung05 研究的结果

Sands, Jacob; Ahn, Myung-Ju; Lisberg, Aaron; Cho, Byoung Chul; Blumenschein, George Jr; Shum, Elaine; Pons Tostivint, Elvire; Goto, Yasushi; Yoh, Kiyotaka; Heist, Rebecca; Shimizu, Junichi; Lee, Jong-Seok; Baas, Paul; Planchard, David; Pérol, Maurice; Felip, Enriqueta; Su, Wu-Chou; Zebger-Gong, Hong; Lan, Lan; Liu, Chelsea; Howarth, Paul; Chiaverelli, Rachel; Paz-Ares, Luis

Characteristics of a CCL21 Gene-Modified Dendritic Cell Vaccine Utilized for a Clinical Trial in Non-Small Cell Lung Cancer

用于非小细胞肺癌临床试验的CCL21基因修饰树突状细胞疫苗的特性

Michael S Oh ,Camelia Dumitras ,Ramin Salehi-Rad ,Linh M Tran ,Kostyantyn Krysan ,Raymond J Lim ,Zhe Jing ,Shahed Tappuni ,Aaron Lisberg ,Edward B Garon ,Steven M Dubinett ,Bin Liu

Datopotamab deruxtecan-associated select adverse events: clinical practices and institutional protocols on prophylaxis, monitoring, and management

达托泊单抗德鲁替康相关特定不良事件:预防、监测和管理方面的临床实践和机构方案

Lisberg, Aaron; Huppert, Laura A; Halmos, Balazs; Ledezma, Blanca; Soto-Romano, Vanessa; Traina, Tiffany A

US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan

美国专家就达托泊单抗德鲁西替康治疗患者口腔炎的预防和管理达成德尔菲共识

Rugo, Hope; Bardia, Aditya; Bruno, Debora S; Ernani, Vinicius; Hamilton, Erika; Heist, Rebecca; Jhaveri, Komal; Levy, Benjamin; Lisberg, Aaron; O'Shaughnessy, Joyce; Sands, Jacob; Spira, Alexander; Tolaney, Sara; Treister, Nathaniel S; Matthews, Cecile; Johnson, Melissa

Vitamin D status in Faroese adults and its association with inflammatory bowel diseases - a cross-sectional study from the FarGen 2 project

法罗群岛成年人维生素D水平及其与炎症性肠病的关系——来自FarGen 2项目的横断面研究

Lisberg, Randi Næss; Rubek Nielsen, Kári; Nattestad Lydersen, Leivur; Didriksen Apol, Katrin; Midjord, Jóngerð; Gray, Olivia; Hendershott, Melissa; Strøm, Marin; Oddmarsdóttir Gregersen, Noomi

Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study

Datopotamab Deruxtecan 治疗晚期或转移性 HR+/HER2- 和三阴性乳腺癌:来自 I 期 TROPION-PanTumor01 研究的结果

Bardia, Aditya; Krop, Ian E; Kogawa, Takahiro; Juric, Dejan; Tolcher, Anthony W; Hamilton, Erika P; Mukohara, Toru; Lisberg, Aaron; Shimizu, Toshio; Spira, Alexander I; Tsurutani, Junji; Damodaran, Senthil; Papadopoulos, Kyriakos P; Greenberg, Jonathan; Kobayashi, Fumiaki; Zebger-Gong, Hong; Wong, Rie; Kawasaki, Yui; Nakamura, Tadakatsu; Meric-Bernstam, Funda

Blocking the dimerization of polyglutamine-expanded androgen receptor protects cells from DHT-induced toxicity by increasing AR turnover

阻断多聚谷氨酰胺扩增的雄激素受体二聚化可通过增加 AR 周转来保护细胞免受 DHT 诱导的毒性

Allison Lisberg, Yuhong Liu, Diane E Merry